Tesaro, Inc., an oncology-focused biopharmaceutical company, announced its participation in two upcoming investor conferences.
WALTHAM, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Tesaro, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences.
The two conferences are:
- The Cantor Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, October 3, 2018.Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to present an overview of the Company’s business and development programs at 11:30 AM ET and will also host meetings with investors.
- The Leerink Partners Roundtable Series: Rare Disease & Oncology at the Lotte New York Palace on Wednesday, October 3, 2018.Mary Lynne Hedley, Ph.D., President and COO of TESARO, and Timothy Pearson, Executive Vice President and CFO of TESARO, will participate in an analyst-led fireside chat at 1:30 PM ET and will also host meetings with investors.
Live webcasts of the presentations at the Cantor and Leerink Partners conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Kate Rausch
1.781.257.2505
krausch@tesarobio.com
